The Society for Women’s Health Research, in its capacity as administrative home of the Coalition to Advance Maternal Therapeutics, will be championing passage of the provisions included in the Advancing Safe Medications for Moms and Babies Act of 2023 (USA). This bill called for the implementation of recommendations made by the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) that have not yet been implemented but would improve the culture around including pregnant and lactating populations in clinical trials.
Among the provisions included in the bill are updating the United States Food and Drug Administration's regulations to remove pregnant women as a vulnerable population; establishing and maintaining a federal clearinghouse of educational materials and current information on trials enrolling pregnant and lactating populations; conducting a public education campaign; and prioritizing pregnant and lactating populations in research projects. Together, these priorities can help address misconceptions about this population’s participation in research, make it easier for patients and their health care providers to find information on active trials and these populations to participation in research.
Measures of success may include having related language included within the fiscal year 2026 appropriations legislation, the re-introduction of the bill in the 119th U.S. Congress, the identification of House and Senate champions for the legislation, and ‘Dear Colleague’ letters on this topic being circulated in Congress.
